CL2012001321A1 - Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes. - Google Patents
Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.Info
- Publication number
- CL2012001321A1 CL2012001321A1 CL2012001321A CL2012001321A CL2012001321A1 CL 2012001321 A1 CL2012001321 A1 CL 2012001321A1 CL 2012001321 A CL2012001321 A CL 2012001321A CL 2012001321 A CL2012001321 A CL 2012001321A CL 2012001321 A1 CL2012001321 A1 CL 2012001321A1
- Authority
- CL
- Chile
- Prior art keywords
- piperidin
- spiro
- indolin
- indan
- inden
- Prior art date
Links
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title 2
- 125000003003 spiro group Chemical group 0.000 title 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26518109P | 2009-11-30 | 2009-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012001321A1 true CL2012001321A1 (es) | 2013-11-15 |
Family
ID=43384775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012001321A CL2012001321A1 (es) | 2009-11-30 | 2012-05-23 | Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8822486B2 (enExample) |
| EP (1) | EP2507228B1 (enExample) |
| JP (1) | JP5709889B2 (enExample) |
| KR (1) | KR101410103B1 (enExample) |
| CN (1) | CN102648195B (enExample) |
| AR (1) | AR078948A1 (enExample) |
| AU (1) | AU2010324987B2 (enExample) |
| BR (1) | BR112012012903A2 (enExample) |
| CA (1) | CA2781292C (enExample) |
| CL (1) | CL2012001321A1 (enExample) |
| CR (1) | CR20120296A (enExample) |
| DO (1) | DOP2012000139A (enExample) |
| EA (1) | EA020507B1 (enExample) |
| EC (1) | ECSP12011930A (enExample) |
| ES (1) | ES2526568T3 (enExample) |
| GT (1) | GT201200164A (enExample) |
| IL (1) | IL219594A0 (enExample) |
| MA (1) | MA33840B1 (enExample) |
| MX (1) | MX2012006233A (enExample) |
| NZ (1) | NZ600203A (enExample) |
| PE (1) | PE20121474A1 (enExample) |
| PH (1) | PH12012501052A1 (enExample) |
| TN (1) | TN2012000248A1 (enExample) |
| TW (1) | TW201141866A (enExample) |
| WO (1) | WO2011066183A1 (enExample) |
| ZA (1) | ZA201203055B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| PH12012501456A1 (en) | 2009-12-25 | 2012-10-29 | Mochida Pharm Co Ltd | Novel 3-hydroxy -5- arylisothiazole derivative |
| AU2011313191A1 (en) | 2010-10-08 | 2013-05-02 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| AR085990A1 (es) | 2011-04-27 | 2013-11-13 | Mochida Pharm Co Ltd | Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen |
| JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| AR087451A1 (es) | 2011-08-17 | 2014-03-26 | Lilly Co Eli | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes |
| WO2014159054A1 (en) * | 2013-03-14 | 2014-10-02 | Janssen Pharmaceutica Nv | Gpr120 agonists for the treatment of type ii diabetes |
| CN105722841A (zh) | 2013-11-14 | 2016-06-29 | 卡迪拉保健有限公司 | 新型杂环化合物 |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN110590767B (zh) * | 2019-08-29 | 2021-10-08 | 南方科技大学 | 一种合成amg837的方法 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| CA2520114A1 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
| US7504506B2 (en) | 2003-11-04 | 2009-03-17 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| CA2579204A1 (en) * | 2004-09-07 | 2006-03-16 | Banyu Pharmaceutical Co., Ltd. | Carbamoyl-substituted spiro derivative |
| MX2009000475A (es) * | 2006-07-19 | 2009-07-10 | Astrazeneca Ab | Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas. |
| EP2072519A4 (en) * | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
| PT2125827E (pt) * | 2006-12-29 | 2010-11-22 | Hoffmann La Roche | Derivados azaespiro |
| ES2446419T3 (es) * | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| TWI421070B (zh) * | 2007-10-26 | 2014-01-01 | Japan Tobacco Inc | 螺化合物及其醫藥用途 |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
-
2010
- 2010-11-08 AR ARP100104151A patent/AR078948A1/es not_active Application Discontinuation
- 2010-11-10 TW TW099138725A patent/TW201141866A/zh unknown
- 2010-11-19 NZ NZ600203A patent/NZ600203A/xx not_active IP Right Cessation
- 2010-11-19 MX MX2012006233A patent/MX2012006233A/es not_active Application Discontinuation
- 2010-11-19 CA CA2781292A patent/CA2781292C/en not_active Expired - Fee Related
- 2010-11-19 BR BR112012012903A patent/BR112012012903A2/pt not_active IP Right Cessation
- 2010-11-19 CN CN201080054116.3A patent/CN102648195B/zh not_active Expired - Fee Related
- 2010-11-19 ES ES10784390.6T patent/ES2526568T3/es active Active
- 2010-11-19 AU AU2010324987A patent/AU2010324987B2/en not_active Ceased
- 2010-11-19 EP EP10784390.6A patent/EP2507228B1/en active Active
- 2010-11-19 PH PH1/2012/501052A patent/PH12012501052A1/en unknown
- 2010-11-19 JP JP2012542076A patent/JP5709889B2/ja not_active Expired - Fee Related
- 2010-11-19 US US13/505,470 patent/US8822486B2/en not_active Expired - Fee Related
- 2010-11-19 EA EA201290416A patent/EA020507B1/ru not_active IP Right Cessation
- 2010-11-19 PE PE2012000730A patent/PE20121474A1/es not_active Application Discontinuation
- 2010-11-19 KR KR1020127013788A patent/KR101410103B1/ko not_active Expired - Fee Related
- 2010-11-19 WO PCT/US2010/057359 patent/WO2011066183A1/en not_active Ceased
-
2012
- 2012-04-25 ZA ZA2012/03055A patent/ZA201203055B/en unknown
- 2012-05-03 IL IL219594A patent/IL219594A0/en unknown
- 2012-05-15 DO DO2012000139A patent/DOP2012000139A/es unknown
- 2012-05-20 EC ECSP12011930 patent/ECSP12011930A/es unknown
- 2012-05-22 TN TNP2012000248A patent/TN2012000248A1/en unknown
- 2012-05-23 CL CL2012001321A patent/CL2012001321A1/es unknown
- 2012-05-28 GT GT201200164A patent/GT201200164A/es unknown
- 2012-05-30 CR CR20120296A patent/CR20120296A/es not_active Application Discontinuation
- 2012-06-21 MA MA34993A patent/MA33840B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL219594A0 (en) | 2012-06-28 |
| US8822486B2 (en) | 2014-09-02 |
| CA2781292A1 (en) | 2011-06-03 |
| CR20120296A (es) | 2012-07-16 |
| MX2012006233A (es) | 2012-07-03 |
| EP2507228B1 (en) | 2014-11-05 |
| PH12012501052A1 (en) | 2013-02-04 |
| JP5709889B2 (ja) | 2015-04-30 |
| CN102648195A (zh) | 2012-08-22 |
| GT201200164A (es) | 2014-02-27 |
| EP2507228A1 (en) | 2012-10-10 |
| US20120220616A1 (en) | 2012-08-30 |
| ZA201203055B (en) | 2013-09-25 |
| AU2010324987B2 (en) | 2014-01-30 |
| KR101410103B1 (ko) | 2014-06-25 |
| CN102648195B (zh) | 2015-01-07 |
| CA2781292C (en) | 2014-04-22 |
| EA201290416A1 (ru) | 2012-11-30 |
| DOP2012000139A (es) | 2012-08-15 |
| TW201141866A (en) | 2011-12-01 |
| AR078948A1 (es) | 2011-12-14 |
| WO2011066183A1 (en) | 2011-06-03 |
| JP2013512277A (ja) | 2013-04-11 |
| MA33840B1 (fr) | 2012-12-03 |
| ECSP12011930A (es) | 2012-07-31 |
| PE20121474A1 (es) | 2012-11-05 |
| EA020507B1 (ru) | 2014-11-28 |
| KR20120088770A (ko) | 2012-08-08 |
| NZ600203A (en) | 2013-09-27 |
| TN2012000248A1 (en) | 2013-12-12 |
| BR112012012903A2 (pt) | 2017-03-01 |
| ES2526568T3 (es) | 2015-01-13 |
| AU2010324987A1 (en) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| CL2013002939A1 (es) | Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
| CL2007003033A1 (es) | Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii. | |
| CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| CL2012000573A1 (es) | Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv. | |
| CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
| CL2009000173A1 (es) | Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros. | |
| CL2013000727A1 (es) | Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c. | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
| CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
| CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
| CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
| CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
| BRPI0916571A2 (pt) | composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto | |
| BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
| CL2008003511A1 (es) | Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. |